USFDA approves 3rd biosimilar: Erelzi, a biosimilar to Enbrel
Posted on02 Sep 2016
TagsBiosimilar, biosimilar of enbrel, black box warning, Erelzi, Etanercept, meaning of black box warning
Comments0
The U.S. Food and Drug Administration today approved Erelzi, for multiple inflammatory diseases. Erelzi is a biosimilar to Enbrel (etanercept), which was originally... Read More
BENEPALI®, the First Etanercept Biosimilar Referencing Enbrel®, Approved in the European Union
The joint venture between Biogen and Samsung BioLogics, Samsung Bioepis, has been granted European Commission (EC) approval for BENEPALI® , an etanercept... Read More